BeyondSpring (NASDAQ:BYSI) Share Price Passes Below Fifty Day Moving Average – Here’s What Happened

Shares of BeyondSpring Inc. (NASDAQ:BYSI) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.41 and traded as low as $0.73. BeyondSpring shares last traded at $0.7420, with a volume of 33,006 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

BeyondSpring Stock Performance

The stock has a market capitalization of $34.50 million, a P/E ratio of -5.99 and a beta of 0.48. The stock has a 50-day simple moving average of $1.39 and a 200 day simple moving average of $1.50.

BeyondSpring (NASDAQ:BYSI) last released its earnings results on Friday, August 14th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.52.

Institutional Trading of BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC boosted its holdings in BeyondSpring Inc. (NASDAQ:BYSI) by 16.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 368,682 shares of the company’s stock after buying an additional 53,198 shares during the period. Geode Capital Management LLC owned approximately 0.91% of BeyondSpring worth $601,000 as of its most recent SEC filing. 40.29% of the stock is owned by hedge funds and other institutional investors.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.